The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial
Open accessAbstract
BACKGROUND: Most HIV-1-infected patients on effective antiretroviral therapy (ART) with plasma HIV-1 RNA levels below the detection limits of commercial assays have residual viremia measurable by more sensitive methods. We assessed whether adding raltegravir lowered the level of residual viremia in such patients. METHODS AND FINDINGS: Patients receiving ART who had plasma HIV-1 RNA levels below 50 copies/mL but detectable viremia by single copy assay (SCA) were randomized to add either raltegravir or placebo to their ART regimen for 12 weeks; patients then crossed-over to the other therapy for an additional 12 weeks while continuing pre-study ART. The primary endpoint was the plasma HIV-1 RNA by SCA averaged between weeks 10 and 12 (10/12) compared between treatment groups. Fifty-three patients were enrolled. The median screening HIV-1 RNA was 1.7 copies/mL. The HIV-1 RNA level at weeks 10/12 did not differ significantly between the raltegravir-intensified (n = 25) and the placebo (n = 24) groups (median 1.2 versus 1.7 copies/mL, p = 0.55, Wilcoxon rank sum test), nor did the change in HIV-1 RNA level from baseline to week 10/12 (median -0.2 and -0.1 copies/mL, p = 0.71, Wilcoxon rank sum test). There was also no significant change in HIV-1 RNA level from weeks 10/12 to weeks 22/24 after patients crossed-over. There was a greater CD4 cell count increase from baseline to week 12 in the raltegravir-intensified group compared with the placebo group (+42 versus -44 cells/mm(3), p = 0.082, Wilcoxon rank sum test), which reversed after the cross-over. This CD4 cell count change was not associated with an effect of raltegravir intensification on markers of CD4 or CD8 cell activation in blood. CONCLUSION: In this randomized, double-blind cross-over study, 12 weeks of raltegravir intensification did not demonstrably reduce low-level plasma viremia in patients on currently recommended ART. This finding suggests that residual viremia does not arise from ongoing cycles of HIV-1 replication and infection of new cells. New therapeutic strategies to eliminate reservoirs that produce residual viremia will be required to eradicate HIV-1 infection. TRIAL REGISTRATION: ClinicalTrials.gov NCT00515827
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hunt, P. W., Martin, J. N., Sinclair, E., Bredt, B., Hagos, E., Lampiris, H., & Deeks, S. G. (2003) · The Journal of Infectious Diseases · doi:10.1086/374786 · Cited by 852
The Challenge of Finding a Cure for HIV Infection
Richman, D. D., Margolis, D. M., Delaney, M., Greene, W. C., Hazuda, D., & Pomerantz, R. J. (2009) · Science · doi:10.1126/science.1165706 · Cited by 846
Self-citationRaltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
Steigbigel, R. T., Cooper, D. A., Kumar, P. N., Eron, J. E., Schechter, M., Markowitz, M., Loutfy, M. R., Lennox, J. L., Gatell, J. M., Rockstroh, J. K., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708975 · Cited by 691
Self-citationLow-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy
Palmer, S., Maldarelli, F., Wiegand, A., Bernstein, B., Hanna, G. J., Brun, S. C., Kempf, D. J., Mellors, J. W., Coffin, J. M., & King, M. S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800050105 · Cited by 638
Self-citationLennox, J. L., DeJesus, E., Lazzarin, A., Pollard, R. B., Madruga, J. V. R., Berger, D. S., Zhao, J., Xu, X., Williams-Diaz, A., Rodgers, A. J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60918-1 · Cited by 625
Palmer, S., Wiegand, A. P., Maldarelli, F., Bazmi, H., Mican, J. M., Polis, M., Dewar, R. L., Planta, A., Liu, S., Metcalf, J. A., et al. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.10.4531-4536.2003 · Cited by 604
Self-citationJ Buzón, M., Massanella, M., Llibre, J. M., Esteve, A., Dahl, V., Puertas, M. C., Gatell, J. M., Domingo, P., Paredes, R., Sharkey, M., et al. (2010) · Nature Medicine · doi:10.1038/nm.2111 · Cited by 551
Self-citationDornadula, G. (1999) · JAMA · doi:10.1001/jama.282.17.1627 · Cited by 463
Dinoso, J. B., Kim, S. Y., Wiegand, A. M., Palmer, S. E., Gange, S. J., Cranmer, L., O'Shea, A., Callender, M., Spivak, A., Brennan, T., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903107106 · Cited by 441
Self-citationHsue, P. Y., Hunt, P. W., Schnell, A., Kalapus, S. C., Hoh, R., Ganz, P., Martin, J. N., & Deeks, S. G. (2009) · AIDS · doi:10.1097/qad.0b013e32832b514b · Cited by 388
ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia
Maldarelli, F., Palmer, S., King, M. S., Wiegand, A., Polis, M. A., Mican, J., Kovacs, J. A., Davey, R. T., Rock-Kress, D., Dewar, R., et al. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030046 · Cited by 333
Self-citationUnderstanding HIV-1 latency provides clues for the eradication of long-term reservoirs
Coiras, M., López-Huertas, M. R., Pérez-Olmeda, M., & Alcamí, J. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2223 · Cited by 288
McMahon, D., Jones, J., Wiegand, A., Gange, S. J., Kearney, M., Palmer, S., McNulty, S., Metcalf, J. A., Acosta, E., Rehm, C., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/650749 · Cited by 223
Self-citationKieffer, T. L., Finucane, M. M., Nettles, R. E., Quinn, T. C., Broman, K. W., Ray, S. C., Persaud, D., & Siliciano, R. F. (2004) · The Journal of Infectious Diseases · doi:10.1086/382488 · Cited by 201
Gandhi, R. T., Spritzler, J., Chan, E., Asmuth, D. M., Rodriguez, B., Merigan, T. C., Hirsch, M. S., Shafer, R. W., Robbins, G. K., & Pollard, R. B. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000226789.51992.3f · Cited by 165
Self-citationHavlir, D. V., Strain, M. C., Clerici, M., Ignacio, C. C., Trabattoni, D., Ferrante, P., & Wong, J. K. (2003) · Journal of Virology · doi:10.1128/jvi.77.20.11212-11219.2003 · Cited by 160
Interaction between endothelium and CD4+CD45RA+ lymphocytes. Role of the human CD38 molecule.
Dianzani, U., Funaro, A., DiFranco, D., Garbarino, G. M., Bragardo, M., Redoglia, V., Buonfiglio, D., Monte, L. B. D., Pileri, A., & Malavasi, F. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.3.952 · Cited by 153
Clement, L. T., Vink, P., & Bradley, G. E. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.145.1.102 · Cited by 141
Goicoechea, M., Smith, D. M., Liu, L., May, S. J., Tenorio, A. R., Ignacio, C. C., LANDAY, A. L., & Haubrich, R. (2006) · The Journal of Infectious Diseases · doi:10.1086/504718 · Cited by 114
Limits on Replenishment of the Resting CD4+ T Cell Reservoir for HIV in Patients on HAART
Sedaghat, A. R., Siliciano, J. D., Brennan, T. P., Wilke, C. O., & Siliciano, R. F. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030122 · Cited by 80
Characterization of Lymphocyte Subpopulations in Cord Blood
Rabian, C., LESAGE, S., Gluckman, É., & Charron, D. J. (1993) · Journal of Hematotherapy · doi:10.1089/scd.1.1993.2.255 · Cited by 67
Interaction between endothelium and CD4+CD45RA+ lymphocytes. Role of the human CD38 molecule.
Dianzani, U., DiFranco, D., G., G., M., B., Redoglia, V., Buonfiglio, D., LB, D. M., A., P., Funaro, A., & Malavasi, F. (1994) · Institutional Research Information System University of Turin (University of Turin) · Cited by 55
Cited by
Saag, M. S., Benson, C. A., Gandhi, R. T., Hoy, J. F., Landovitz, R. J., Mugavero, M. J., Sax, P. E., Smith, D. M., Thompson, M. A., Buchbinder, S. P., et al. (2018) · JAMA · doi:10.1001/jama.2018.8431 · Cited by 698
Self-citationComparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies
Eriksson, S., Graf, E. H., Dahl, V., Strain, M. C., Yukl, S. A., Lysenko, E. S., Bosch, R. J., Lai, J., Chioma, S., Emad, F., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003174 · Cited by 567
Self-citationTowards an HIV cure: a global scientific strategy
The International AIDS Society Scientific Working Group on HIV Cure (2012) · Nature Reviews Immunology · doi:10.1038/nri3262 · Cited by 554
Siliciano, R. F., & Greene, W. C. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007096 · Cited by 513
Redefining the Viral Reservoirs that Prevent HIV-1 Eradication
Eisele, E., & Siliciano, R. F. (2012) · Immunity · doi:10.1016/j.immuni.2012.08.010 · Cited by 474
Metadata
- Authors
- Gandhi, R. T., Zheng, L., Bosch, R. J., Chan, E. S., Margolis, D. M., Read, S., Kallungal, B., Palmer, S., Medvik, K., Lederman, M. M., Alatrakchi, N., Jacobson, J. M., Wiegand, A., Kearney, M., Coffin, J. M., Mellors, J. W., Eron, J. J., & on behalf of the AIDS Clinical Trials Group A5244 team
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-08-10
- Volume
- 7
- Issue
- 8
- Pages
- e1000321
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2113669930
- Cited by
- 304
- References
- 22
- FWCI
- 21.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.